RecruitingPhase 2NCT06277154

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Studying Angiosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
HRYZ Biotech Co.
Principal Investigator
Xing Zhang
Sun Yat-Sen University Cancer Center
Intervention
MASCT-I(biological)
Enrollment
148 enrolled
Eligibility
18-70 years · All sexes
Timeline
20242027

Study locations (1)

Collaborators

Sun Yat-Sen University Cancer Center

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06277154 on ClinicalTrials.gov

Other trials for Angiosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Angiosarcoma

← Back to all trials